
    
      This is an open label, nonrandomized, single center, phase I cohort study, involving reduced
      intensity conditioning, followed by a single infusion of autologous CD34+PBSC, transduced
      with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS (MUT6)(VSVg)) also known as
      (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII
      (BDDFVIII) in up to five hemophilia A patients with inhibitors to FVIII.
    
  